Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AML Cell Vaccine in high-risk MDS and AML
NCT02493829Phase 1Unknown
- Sponsor
- King's College London
- Start
- May 2017
- Primary completion
- May 2020
- Modality
- Gene Editing, Gene Silencing, Vaccines & Immunotherapeutics
01
Overview
Phase 1, open-label trial of AML Cell Vaccine in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by King's College London. Primary endpoints: Vaccine-related toxicity based on the NCI criteria V4.0 at 52 weeks and Frequency and severity of adverse events to the AML cell vaccine at 52 weeks. Status: unknown.
02
Drugs
AML Cell Vaccine
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT02493829.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02493829.